propionylaminoacetic acid methyl ester | 4396-63-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: propionylaminoacetic acid methyl ester
• 英文别名: methyl 2-(propanoylamino)-acetate；methyl 2-(propanoylamino)acetate；propionylglycine methyl ester；methyl propionylglycinate；Propionylglycinmethylester；Methyl (propionylamino)acetate
• CAS: 4396-63-8
• 化学式: C₆H₁₁NO₃
• mdl: MFCD05660032
• 分子量: 145.158
• InChiKey: QZXTYJDHWPMJLY-UHFFFAOYSA-N

物化性质

• 沸点：
  259.7±13.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)
• 保留指数：
  1171

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  propionylaminoacetic acid methyl ester 在 氨 、 氯化铵 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以30%的产率得到N-carbamoylmethylpropionamide
  参考文献：
  名称：

  2-Pyrrolidinone moiety is not critical for the cognition-enhancing activity of piracetam-like drugs

  摘要：

  Following the indications of previous work, 2-pyrrolidinone moiety of piracetam and piracetam-like compounds has been opened to the corresponding amide derivatives. As found previously in the case of 1,4-diazabicyclo[4.3.0]nonan-9-one compounds, the cognition-enhancing activity of 2-pyrrolidinone compounds is maintained in most cases, suggesting that this moiety is not crucial for activity.

  DOI：

  10.1016/s0014-827x(03)00111-3
• 作为产物：
  描述：

  N-acryloyl-glycine O-methyl ester 在 钯 氢气 作用下， 以 重水 为溶剂， 反应 1.0h， 生成 propionylaminoacetic acid methyl ester
  参考文献：
  名称：

  通过载脂蛋白-铁蛋白笼中提供的Pd纳米簇进行尺寸选择性烯烃加氢。

  摘要：

  DOI：

  10.1002/anie.200353436

文献信息

• THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT
  申请人：Kataoka Tohru

  公开号：US20140194412A1

  公开（公告）日：2014-07-10

  The present invention provides an anticancer drug having a Ras function inhibitory action. The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I′): wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供一种具有Ras功能抑制作用的抗癌药物。 本发明提供一种包括由式(I′)表示的化合物的Ras功能抑制剂： 其中每个符号如本说明书中所定义，或其盐。
• Carboxylic Acid Deoxyfluorination and One-Pot Amide Bond Formation Using Pentafluoropyridine (PFP)
  作者：William D. G. Brittain、Steven L. Cobb

  DOI：10.1021/acs.orglett.1c01953

  日期：2021.8.6

  cheap commercially available reagent, in the deoxyfluorination of carboxylic acids to acyl fluorides. The acyl fluorides can be formed from a range of acids under mild conditions. We also demonstrate that PFP can be utilized in a one-pot amide bond formation via in situ generation of acyl fluorides. This one-pot deoxyfluorination amide bond-forming reaction gives ready access to amides in yields of ≤94%

  这项工作描述了五氟吡啶 (PFP​​)，一种廉价的市售试剂，在羧酸脱氧氟化成酰氟中的应用。酰氟可以在温和条件下由一系列酸形成。我们还证明 PFP 可用于通过原位生成酰氟形成一锅酰胺键。这种一锅法脱氧氟化酰胺键形成反应可以很容易地以≤94% 的产率获得酰胺。
• [EN] DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)<br/>[FR] BÊTA-LACTONES DISUBSTITUÉS EN TANT QU'INHIBITEURS DE L'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA)
  申请人：UNIV CALIFORNIA

  公开号：WO2013078430A1

  公开（公告）日：2013-05-30

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-酰乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，这两种物质是NAAA的底物，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的疾病的方法。
• Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)
  申请人：The Regents of the University of California

  公开号：US09353075B2

  公开（公告）日：2016-05-31

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-酰基乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的紊乱的方法。
• [EN] QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PIPÉRIDINE DU TYPE QUINAZOLIN-4(3H)-ONE ET UTILISATIONS DE CEUX-CI
  申请人：PURDUE PHARMA LP

  公开号：WO2014102589A1

  公开（公告）日：2014-07-03

  The present disclosure relates to Quinazolin-4(3H)-one-Type Piperidine Compounds, such as those of Formule (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Q, Y1, Z, A, B, E, and a are as defined herein; compositions comprising an effective amount of a Quinazolin-4(3H)-one-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Quinazolin-4(3 H)-one-Type Piperidine Compound.

  本公开涉及喹唑啉-4(3H)-酮型哌啶化合物，例如公式(I)中的化合物及其药学上可接受的盐和溶剂，其中R1、R2、R3、Q、Y1、Z、A、B、E和a如本文所定义；包含有效量喹唑啉-4(3H)-酮型哌啶化合物的组合物；以及治疗或预防疼痛等疾病的方法，包括向需要的动物施用有效量喹唑啉-4(3H)-酮型哌啶化合物。

表征谱图